S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
All the trading advice you’ve ever received boils down to this (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
All the trading advice you’ve ever received boils down to this (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

NovoCure Stock Price, News & Analysis (NASDAQ:NVCR)

$12.50
+0.23 (+1.87%)
(As of 12/1/2023 ET)
Compare
Today's Range
$11.76
$12.55
50-Day Range
$11.13
$17.34
52-Week Range
$10.87
$120.03
Volume
1.26 million shs
Average Volume
1.32 million shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.29

NovoCure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
262.3% Upside
$45.29 Price Target
Short Interest
Healthy
8.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.13mentions of NovoCure in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$4,832 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.04) to ($1.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

466th out of 951 stocks

Surgical & Medical Instruments Industry

52nd out of 93 stocks


NVCR stock logo

About NovoCure Stock (NASDAQ:NVCR)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR Stock Price History

NVCR Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Novocure to Cut 13% of Workforce in Restructuring
Novocure To Reduce 13% Of Current Workforce - Quick Facts
NovoCure: Significant Upside Even Without A Breakthrough
Is Novocure Stock a Buy?
The NovoCure Ltd (NVCR) Company: A Short SWOT Analysis
H.C. Wainwright Reaffirms Their Hold Rating on NovoCure (NVCR)
Why Novocure Stock Was Sick Today
NovoCure Ltd (NVCR) Reports Q3 2023 Financial Results
NovoCure (NVCR) Q3 2023 Earnings Call Transcript
Novocure Reports Third Quarter 2023 Financial Results
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,320
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.29
High Stock Price Target
$51.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+262.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-92,530,000.00
Pretax Margin
-36.86%

Debt

Sales & Book Value

Annual Sales
$537.84 million
Book Value
$3.68 per share

Miscellaneous

Free Float
100,802,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.52
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














NVCR Stock Analysis - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price target for 2024?

8 equities research analysts have issued 1-year target prices for NovoCure's stock. Their NVCR share price targets range from $25.00 to $51.00. On average, they predict the company's share price to reach $45.29 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2023?

NovoCure's stock was trading at $73.35 at the start of the year. Since then, NVCR stock has decreased by 83.0% and is now trading at $12.50.
View the best growth stocks for 2023 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NVCR earnings forecast
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, October, 26th. The medical equipment provider reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.05. The medical equipment provider had revenue of $127.30 million for the quarter, compared to analysts' expectations of $128.75 million. NovoCure had a negative trailing twelve-month return on equity of 46.89% and a negative net margin of 39.14%. The firm's revenue for the quarter was down 2.8% on a year-over-year basis. During the same period last year, the firm posted ($0.25) earnings per share.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
Who are NovoCure's major shareholders?

NovoCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Baillie Gifford & Co. (6.38%), Morgan Stanley (1.02%), Palo Alto Investors LP (0.62%), Charles Schwab Investment Management Inc. (0.51%) and Northern Trust Corp (0.41%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NVCR) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -